Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo- and olanzapine-controlled study

American Journal of Psychiatry

Volumn 168, Issue 9, 2011, Pages 957-967

  Meltzer, Herbert Y ^a,b,c,d,e,f   Cucchiaro, Josephine ^a,b,c,d,e,f   Silva, Robert ^a,b,c,d,e,f   Ogasa, Masaaki ^a,b,c,d,e,f   Phillips, Debra ^a,b,c,d,e,f   Xu, Jane ^a,b,c,d,e,f   Kalali, Amir H ^a,b,c,d,e,f   Schweizer, Edward ^a,b,c,d,e,f   Pikalov, Andrei ^a,b,c,d,e,f   Loebel, Antony ^a,b,c,d,e,f  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUNOVION PHARMACEUTICALS INC   (United States)

^c KANAZAWA UNIVERSITY   (Japan)

^d IQVIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Paladin Consulting Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LURASIDONE; OLANZAPINE; PLACEBO;

ADULT; AGED; AGITATION; AKATHISIA; ANXIETY; APPETITE; ARTICLE; BACKACHE; BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSTONIA; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HYPERSALIVATION; INSOMNIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL STIFFNESS; NAUSEA; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; PSYCHOSIS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TOOTH PAIN; TREMOR; VITAL SIGN; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; PATIENT ADMISSION; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME;

EID: 80052477010     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.10060907     Document Type: Article

References (30)

1. Meltzer HY, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251:238-246
2. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124:57-73
3. Arranz MJ, de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12:707-747
4. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
5. Vandel P, Talon JM, Haffen E, Sechter D: Pharmacogenetics and drug therapy in psychiatry: the role of the CYP2D6 polymorphism. Curr Pharm Des 2007; 13:241-250
6. Ishiyama T, Loebel A, Cucchiaro J, Horisawa T, Tokuda K, Maasaki O, Ishibashi T, Stahl SM: Comparative receptor binding profile of lurasidone and other first and second generation antipsychotics, in Research Abstracts to the 2010 Annual Meeting. Washington, DC , American Psychiatric Association, 2010, p 213
7. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A: Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:829-836
8. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20):22-33
9. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S: Olanzapine for schizophrenia. Cochrane Database Syst Rev 2005; 2:CD001359
10. Davis JM, Chen N: Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24:192-208
11. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
12. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58:538-546
13. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
14. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
15. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
16. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC , US Department of Health, Education, and Welfare, 1976, pp 534-537
17. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, Quon MJ, Baron AD: Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001; 86:5457-5464
18. Brechenmacher T, Xu J, Dmitrienko A, Tamhane AC: A mixture gatekeeping procedure based on the Hommel test for clinical trial applications. J Biopharm Stat 2011; 21:748-767
19. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RSE: Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs ziprasidone. Schizophr Res 2011; 127:188-194
20. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Ohki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M: Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010; 334:171-181
21. Meyer JM, Loebel AD, Schweizer E: Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009; 18:1715-1726
22. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL: H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28:519-526
23. Correll CU, Druss BG, Lombardo I, O'Gorman C , Harnett JP, Sanders KN, Alvir JM, Cuffel BJ: Findings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv 2010; 61:892-898
24. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65:267-272
25. Newcomer JW: Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68(suppl 4):8-13
26. Raz I, Eldor R, Cernea S, Shafrir E: Diabetes: insulin resistance and derangements in lipid metabolism: cure through intervention in fat transport and storage. Diabetes Metab Res Rev 2005; 21:3-14
27. Bostwick JR, Guthrie SK, Ellingrod VL: Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 2009; 29:64-73
28. Leucht S, Komossa K, Rummel-Kluge C , Corves C , Hunger H, Schmid F, Asenjo Lobos C , Schwarz S, Davis JM: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152-163
29. Citrome L: Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011; 65:189-210
30. Citrome L, Reist C , Palmer L, Montejano L, Lenhart G, Cuffel B, Harnett J, Sanders KN: Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr Res 2009; 108:238-244